Clinical Roundup Hemokine modulatory regimen shows promise for TNBC in phase I study November 22, 2024Vol.50 No.44
Clinical Roundup Fralin Biomedical Research Institute spinoff company focuses on peptide drugs targeting cancer stem cells November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves new alternative standard related to mammography report assessments November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves revumenib for r/r acute leukemia with a KMT2A translocation November 22, 2024Vol.50 No.44
Drugs & Targets FDA approves first companion diagnostic for lung cancer drug November 22, 2024Vol.50 No.44
Drugs & Targets CHMP issues positive opinion of Sarclisa for transplant-ineligible newly diagnosed MM November 22, 2024Vol.50 No.44
Drugs & Targets EC approves of Elahere for treatment of platinum-resistant ovarian cancer November 22, 2024Vol.50 No.44
Drugs & Targets LINDIS Biotech signs licensing agreement with Pharmanovia for the commercialization of catumaxomab November 22, 2024Vol.50 No.44
